Home/ImmuneSensor Therapeutics/Thomas W. Dubensky, Jr., Ph.D.
TW

Thomas W. Dubensky, Jr., Ph.D.

President and Chief Executive Officer

ImmuneSensor Therapeutics

ImmuneSensor Therapeutics Pipeline

DrugIndicationPhase
IMSA101Oncology (STING Agonist)Phase 1
IMSB301Inflammatory/Autoimmune Diseases (cGAS Inhibitor)Phase 1